Neuroendocrine Tumor Treatment Market: Size, Share, Growth, Trends, Regions, Forecast To 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Neuroendocrine Tumor Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $3.19 billion In 2028 At A CAGR Of 10.3%.

The neuroendocrine tumor treatment market size has grown rapidly in recent years. It will grow from $1.94 billion in 2023 to $2.16 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to clinical research and understanding, awareness and education, specialized medical expertise, advancements in radiation therapy, supportive care services.

The neuroendocrine tumor treatment market size is expected to see rapid growth in the next few years. It will grow to $3.19 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to precision medicine advancements, immunotherapy innovations, minimally invasive procedures, rising incidence rates, telemedicine and remote care. Major trends in the forecast period include advancements in diagnostic technologies, peptide receptor radionuclide therapy (prrt) advancements, nanotechnology in drug delivery, emerging radiopharmaceuticals, cross-disciplinary collaboration.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=12248&type=smp

Neuroendocrine Tumor Treatment Market Major Segments
The neuroendocrine tumor treatment market covered in this report is segmented -

1) By Product: Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others Products
2) By Indication: Lungs, Pancreas, Gastrointestinal, Others Indications
3) By End-Users: Hospitals, Oncology Centers, Other End-Users

Key Driver - Rising Neuroendocrine Tumors Fuel Treatment Market Growth

The growing prevalence of neuroendocrine tumors is expected to propel the growth of the neuroendocrine tumor treatment market going forward. Neuroendocrine tumors (NETs) are a type of rare tumor that originates from neuroendocrine cells. Neuroendocrine tumor treatment is an essential process for curing neuroendocrine tumors and is used to control symptoms, control tumor growth, and use radiation therapy to kill tumor cells. For instance, in March 2023, according to the reports shared by the American Society of Clinical Oncology (ASCO), a US-based professional organization, more than 12,000 people in the US are diagnosed with neuroendocrine tumors each year, and approximately 171,000 people are living with this diagnosis in 2023. Furthermore, in August 2022, according to Cancer Australia, an Australia-based cancer control agency, in Australia, 5,437 people were diagnosed with neuroendocrine tumors in 2022, which is 3.4% of all new cases diagnosed in 2022. Therefore, the growing prevalence of neuroendocrine tumors is driving the growth of the neuroendocrine tumor treatment market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=12248&type=smp

Prominent Trend - Clinical Trials Fuel Innovation In Neuroendocrine Tumor Treatment

Clinical drug development for treatment is a key trend gaining popularity in the neuroendocrine tumor treatment market. Major companies operating in the neuroendocrine tumor treatment market are developing innovative therapies to sustain their position in the market. For instance, in October 2022, Viewpoint Molecular Targeting, Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA), a US-based federal agency, has granted fast-track designation for the development of [212Pb] VMT-α-NET for the treatment of patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs). VMT-α-NET is a targeted alpha-particle therapy (TAT) designed to kill cancer cells that selectively express somatostatin receptors. The FDA's fast-track designation is intended to expedite the development and review of [212Pb] VMT-α-NET for treating NETs. This designation is given to drugs that have the potential to provide a significant improvement in the safety or effectiveness of treatment for a severe condition.

Neuroendocrine Tumor Treatment Market Players
Major companies operating in the neuroendocrine tumor treatment market report are Pfizer Inc., F Hoffmann-La Roche AG, Abbvie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca, GlaxoSmithKline PLC, Takeda Pharmaceutical, Eli Lilly And Company, Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Servier, Teva Pharmaceutical Industries Ltd., Ipsen Pharma SAS, Exelixis Inc., Advanced Accelerator Applications SA, Hutchison Medipharma Ltd., Dauntless Pharmaceuticals Inc., Tarveda Therapeutics, GlycoMira Therapeutics Inc, AVEO Pharmaceuticals Inc., Progenics Pharmaceuticals Inc., Callisto Pharmaceuticals Pvt Ltd., Chiasma Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/neuroendocrine-tumor-treatment-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the neuroendocrine tumor treatment market in 2023. The regions covered in the neuroendocrine tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Neuroendocrine Tumor Treatment Market Report Structure
3. Neuroendocrine Tumor Treatment Market Trends And Strategies
4. Neuroendocrine Tumor Treatment Market - Macro Economic Scenario
5. Neuroendocrine Tumor Treatment Market Size And Growth
…..
27. Neuroendocrine Tumor Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.